ArticleJournal of clinical tuberculosis and other mycobacterial diseases2026
Efficacy and safety of an intravenous amikacin-containing regimen as initial therapy in
Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The global incidence of Methods: This retrospective study included patients with cavitary MAC-PD who received an AMK-IV-containing regimen as initial therapy at Kurashiki Central Hospital between September 2021 and July 2024. AMK-IV dosing was adjusted based on therapeutic drug monitoring (TDM). The primary outcome was sputum culture conversion. Secondary outcomes included radiologic improvement, adverse events, recurrence, and all-cause mortality. Clinical characteristics and outcomes were compared between patients aged ≥75 and < 75 years. Results: Twenty-one patients were analyzed (aged ≥75 years, Conclusion: AMK-IV added to a standard regimen for cavitary MAC-PD may be effective and safe. In this TDM-guided protocol, favorable outcomes were observed despite lower peak concentrations than those generally recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.